Valproic acid reduces neuritic plaque formation and improves learning deficits in APPSwe/PS1A246E transgenic mice via preventing the prenatal hypoxia-induced down-regulation of neprilysin

CNS Neuroscience and Therapeutics

Volumn 20, Issue 3, 2014, Pages 209-217

  Wang, Zheng ^a,b   Zhang, Xiao Jie ^a   Li, Ting ^a   Li, Jia ^a   Tang, Yu ^a   Le, Weidong ^a,c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

^c DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's Disease; Neprilysin; Prenatal Hypoxia; Valproic Acid

Indexed keywords

ALZHEIMER'S DISEASE; NEPRILYSIN; PRENATAL HYPOXIA; VALPROIC ACID;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANOXIA; CHROMATIN IMMUNOPRECIPITATION; DOWN-REGULATION; FEMALE; HUMANS; LEARNING DISORDERS; MALE; MICE; MICE, TRANSGENIC; MUTATION; NEPRILYSIN; NEURITES; PLAQUE, AMYLOID; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PRESENILIN-1; VALPROIC ACID;

EID: 84894227393     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12186     Document Type: Article

References (52)

1. Hama E, Saido TC. Etiology of sporadic Alzheimer's disease: somatostatin, neprilysin, and amyloid beta peptide. Med Hypotheses 2005;65:498-500.
2. Selkoe DJ. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol 1998;8:447-453.
3. Zhang YW, Xu H. Molecular and cellular mechanisms for Alzheimer's disease: understanding APP metabolism. Curr Mol Med 2007;7:687-696.
4. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984;120:885-890.
5. Zheng H, Koo EH. The amyloid precursor protein: beyond amyloid. Mol Neurodegener 2006;1:5.
6. Marr RA, Guan H, Rockenstein E, et al. Neprilysin regulates amyloid Beta peptide levels. J Mol Neurosci 2004;22:5-11.
7. Martins IJ, Hone E, Foster JK, et al. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry 2006;11:721-736.
8. Lahiri DK, Maloney B, Basha MR, Ge YW, Zawia NH. How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the "LEARn" model (latent early-life associated regulation) may explain the triggering of AD. Curr Alzheimer Res 2007;4:219-228.
9. Visootsak J, Sherman S. Neuropsychiatric and behavioral aspects of trisomy 21. Curr Psychiatry Rep 2007;9:135-140.
10. Bazan NG, Palacios-Pelaez R, Lukiw WJ. Hypoxia signaling to genes: significance in Alzheimer's disease. Mol Neurobiol 2002;26:283-298.
11. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 2004;16:1-13.
12. Skoog I, Gustafson D. Update on hypertension and Alzheimer's disease. Neurol Res 2006;28:605-611.
13. Li L, Zhang X, Yang D, Luo G, Chen S, Le W. Hypoxia increases Abeta generation by altering beta - and gamma-cleavage of APP. Neurobiol Aging 2009;30:1091-1098.
14. Zhang X, Li L, Xie W, et al. Prenatal hypoxia may aggravate the cognitive impairment and Alzheimer's disease neuropathology in APPSwe/PS1A246E transgenic mice. Neurobiol Aging 2013;34:663-678.
15. Wang Z, Yang D, Zhang X, et al. Hypoxia-induced down-regulation of neprilysin by histone modification in mouse primary cortical and hippocampal neurons. PLoS ONE 2011;6:e19229.
16. Zhang X, Le W. Pathological role of hypoxia in Alzheimer's disease. Exp Neurol 2010;223:299-303.
17. Carson JA, Turner AJ. Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases? J Neurochem 2002;81:1-8.
18. Fisk L, Nalivaeva NN, Boyle JP, Peers CS, Turner AJ. Effects of hypoxia and oxidative stress on expression of neprilysin in human neuroblastoma cells and rat cortical neurones and astrocytes. Neurochem Res 2007;32:1741-1748.
19. Miners JS, Van Helmond Z, Chalmers K, Wilcock G, Love S, Kehoe PG. Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J Neuropathol Exp Neurol 2006;65:1012-1021.
20. Honig LS, Kukull W, Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology 2005;64:494-500.
21. Schneider JA, Wilson RS, Cochran EJ, et al. Relation of cerebral infarctions to dementia and cognitive function in older persons. Neurology 2003;60:1082-1088.
22. Zhang X, Zhou K, Wang R, et al. Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. J Biol Chem 2007;282:10873-10880.
23. Anderson CJ, Hoare SF, Ashcroft M, Bilsland AE, Keith WN. Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms. Oncogene 2006;25:61-69.
24. Nalivaeva NN, Fisk LR, Belyaev ND, Turner AJ. Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res 2008;5:212-224.
25. Plattner F, Angelo M, Giese KP. The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem 2006;281:25457-25465.
26. Yoder JA, Soman NS, Verdine GL, Bestor TH. DNA (cytosine-5)-methyltransferases in mouse cells and tissues. Studies with a mechanism-based probe. J Mol Biol 1997;270:385-395.
27. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999;99:247-257.
28. Nguyen CT, Weisenberger DJ, Velicescu M, et al. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Res 2002;62:6456-6461.
29. Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998;393:386-389.
30. Fahrner JA, Eguchi S, Herman JG, Baylin SB. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res 2002;62:7213-7218.
31. Czuczwar SJ, Patsalos PN. The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs 2001;15:339-350.
32. Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK, Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem 2001;276:31674-31683.
33. Bidzan L, Grabowski J, Dutczak B, Bidzan M. Impact of treatment with acetylcholinesterase inhibitors, valproic acid and antipsychotics on aggressive behaviour in Alzheimer's type dementia. Psychiatr Pol 2012;46:361-372.
34. Long Z, Zheng M, Zhao L, et al. Valproic acid attenuates neuronal loss in the brain of APP/PS1 double transgenic Alzheimer's disease mice model. Curr Alzheimer Res 2013;10:261-269.
35. Hu JP, Xie JW, Wang CY, et al. Valproate reduces tau phosphorylation via cyclin-dependent kinase 5 and glycogen synthase kinase 3 signaling pathways. Brain Res Bull 2011;85:194-200.
36. Nuutinen T, Suuronen T, Kauppinen A, Salminen A. Valproic acid stimulates clusterin expression in human astrocytes: Implications for Alzheimer's disease. Neurosci Lett 2010;475:64-68.
37. Smith AM, Gibbons HM, Dragunow M. Valproic acid enhances microglial phagocytosis of amyloid-beta(1-42). Neuroscience 2010;169:505-515.
38. Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai LH. Recovery of learning and memory is associated with chromatin remodelling. Nature 2007;447:178-182.
39. Borchelt DR, Ratovitski T, Van Lare J, et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997;19:939-945.
40. Yamamoto T, Hirano A. A comparative study of modified Bielschowsky, Bodian and thioflavin S stains on Alzheimer's neurofibrillary tangles. Neuropathol Appl Neurobiol 1986;12:3-9.
41. Ishimaru F, Shipp MA. Analysis of the human CD10/neutral endopeptidase 24.11 promoter region: two separate regulatory elements. Blood 1995;85:3199-3207.
42. Li C, Booze RM, Hersh LB. Tissue-specific expression of rat neutral endopeptidase (neprilysin) mRNAs. J Biol Chem 1995;270:5723-5728.
43. Maruyama M, Higuchi M, Takaki Y, et al. Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease. Ann Neurol 2005;57:832-842.
44. Hersh LB, Rodgers DW. Neprilysin and amyloid beta peptide degradation. Curr Alzheimer Res 2008;5:225-231.
45. Wang R, Zhang YW, Zhang X, et al. Transcriptional regulation of APH-1A and increased gamma-secretase cleavage of APP and Notch by HIF-1 and hypoxia. FASEB J 2006;20:1275-1277.
46. Lee PH, Hwang EM, Hong HS, Boo JH, Mook-Jung I, Huh K. Effect of ischemic neuronal insults on amyloid precursor protein processing. Neurochem Res 2006;31:821-827.
47. Sun X, He G, Qing H, et al. Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci USA 2006;103:18727-18732.
48. Abdolmaleky HM, Cheng KH, Faraone SV, et al. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum Mol Genet 2006;15:3132-3145.
49. Morrison BE, Majdzadeh N, D'Mello SR. Histone deacetylases: focus on the nervous system. Cell Mol Life Sci 2007;64:2258-2269.
50. Scarpa S, Fuso A, D'Anselmi F, Cavallaro RA. Presenilin 1 gene silencing by S-adenosylmethionine: a treatment for Alzheimer disease. FEBS Lett 2003;541:145-148.
51. Jacobsen JS, Comery TA, Martone RL, et al. Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade. Proc Natl Acad Sci USA 2008;105:8754-8759.
52. Qing H, He G, Ly PT, et al. Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J Exp Med 2008;205:2781-2789.